Notice of Class Action Lawsuit for GRAIL Shareholders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the NHS-Galleri trial, resulting in investor losses when the true information was revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could adversely affect the outcome of the lawsuit.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to rise
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 59.810
Low
38.00
Averages
60.86
High
83.71
Current: 59.810
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the NHS-Galleri trial, resulting in investor losses when the true information was revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could adversely affect the outcome of the lawsuit.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026, alleging that the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that the defendants made materially false statements and concealed adverse facts about the NHS Galleri trial's results, particularly failing to demonstrate the feasibility of a significant reduction in Stage III-IV cancers, which misled investors.
- Stock Price Impact: Following the announcement on February 19, 2026, that the NHS Galleri trial did not show a statistically significant reduction in Stage III-IV cancers, GRAIL's stock price fell sharply, indicating a negative market sentiment towards the company's future prospects.
- Investor Action: Investors are urged to apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in asserting their legal rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is facing allegations that its financial results from April 2024 to April 2026 were distorted due to the premature recognition of customer orders, which concealed weakening demand and could impact the company's future financing capabilities.
- PicS Compliance Issues: PicS N.V. is accused of failing to disclose deficiencies in its credit evaluation procedures prior to its 2026 IPO, leading to the reclassification of approximately R$590 million in exposures and an incremental ECL charge of R$88 million, potentially damaging its market reputation and investor confidence.
- Verra Business Risks: Verra Mobility Corporation's growth strategy for its Commercial Services business is under scrutiny due to its reliance on a contract extension with Avis, with allegations that it downplayed the risk of major rental car companies replacing its services with in-house solutions, making its 2026 performance guidance increasingly unlikely to be met.
- Grail Misleading Statements: Grail, Inc. is accused of failing to accurately reflect potential trends in its clinical trial data, misleading investors about its business prospects, which could adversely affect its future financing and market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the prospects of its NHS-Galleri trial for Stage III-IV cancers, concealing adverse facts while presenting the trial positively, resulting in investor losses when the truth emerged.
- Market Reaction Impact: GRAIL's overstated optimism about the NHS-Galleri study, which ignored data suggesting that the three-year timeframe was insufficient to demonstrate the successful achievement of the study's primary endpoint, rendered its public statements false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investor interests.
See More
Reminder of Shareholder Class Action Lawsuits
- Grail Lawsuit Details: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Verra Lawsuit Overview: The class action lawsuit against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, with investors needing to apply by August 4, 2026, to seek legal recourse as lead plaintiffs.
- BitGo Lawsuit Insights: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance, with a deadline of August 7, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm that has recovered hundreds of millions for defrauded shareholders since its inception in 2000, emphasizing its commitment to providing robust legal representation for investors.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock dropped 50.55% from $101.53 to $50.21 following the February 19, 2026 announcement that its NHS-Galleri trial failed to meet its primary endpoint, severely impacting investor confidence and market performance.
- Class Action Initiated: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed its NHS-Galleri trial was designed for three years to reduce late-stage cancer cases, but the lawsuit argues this timeframe was insufficient to demonstrate the primary endpoint, potentially misleading investors about the company's prospects.
- Legal Consequences and Impact: The lawsuit could result in significant financial liabilities for GRAIL, affecting its future fundraising capabilities and market reputation, thereby intensifying investor skepticism regarding its business model.
See More
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the NHS-Galleri trial, resulting in investor losses when the true information was revealed, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its expertise and successful track record in this field.
- Investor Guidance: Investors are advised to select counsel with proven success in securities litigation to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries, which could adversely affect the outcome of the lawsuit.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased shares between May 13, 2025, and February 19, 2026, alleging that the company concealed critical information regarding the NHS Galleri trial, resulting in investor losses.
- Allegation Details: The complaint claims that the defendants made materially false statements and concealed adverse facts about the NHS Galleri trial's results, particularly failing to demonstrate the feasibility of a significant reduction in Stage III-IV cancers, which misled investors.
- Stock Price Impact: Following the announcement on February 19, 2026, that the NHS Galleri trial did not show a statistically significant reduction in Stage III-IV cancers, GRAIL's stock price fell sharply, indicating a negative market sentiment towards the company's future prospects.
- Investor Action: Investors are urged to apply by August 4, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations to assist affected investors in asserting their legal rights.
See More
Multiple Companies Face Class Action Lawsuits
- Badger Meter Lawsuit: Badger Meter, Inc. is facing allegations that its financial results from April 2024 to April 2026 were distorted due to the premature recognition of customer orders, which concealed weakening demand and could impact the company's future financing capabilities.
- PicS Compliance Issues: PicS N.V. is accused of failing to disclose deficiencies in its credit evaluation procedures prior to its 2026 IPO, leading to the reclassification of approximately R$590 million in exposures and an incremental ECL charge of R$88 million, potentially damaging its market reputation and investor confidence.
- Verra Business Risks: Verra Mobility Corporation's growth strategy for its Commercial Services business is under scrutiny due to its reliance on a contract extension with Avis, with allegations that it downplayed the risk of major rental car companies replacing its services with in-house solutions, making its 2026 performance guidance increasingly unlikely to be met.
- Grail Misleading Statements: Grail, Inc. is accused of failing to accurately reflect potential trends in its clinical trial data, misleading investors about its business prospects, which could adversely affect its future financing and market performance.
See More
GRAIL, Inc. Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against GRAIL, Inc. for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 13, 2025, and February 19, 2026, with a deadline to contact the firm by August 4, 2026.
- False Statement Allegations: The complaint alleges that GRAIL misled investors regarding the prospects of its NHS-Galleri trial for Stage III-IV cancers, concealing adverse facts while presenting the trial positively, resulting in investor losses when the truth emerged.
- Market Reaction Impact: GRAIL's overstated optimism about the NHS-Galleri study, which ignored data suggesting that the three-year timeframe was insufficient to demonstrate the successful achievement of the study's primary endpoint, rendered its public statements false and materially misleading throughout the class period.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to join the lawsuit to recover losses, highlighting its specialization in securities class action lawsuits and shareholder rights litigation to protect investor interests.
See More
Reminder of Shareholder Class Action Lawsuits
- Grail Lawsuit Details: The class action lawsuit against Grail, Inc. alleges that the company made materially false or misleading statements between May 13, 2025, and February 19, 2026, impacting investor decisions, with a deadline of August 4, 2026, for investors to apply as lead plaintiffs to protect their rights.
- Verra Lawsuit Overview: The class action lawsuit against Verra Mobility Corporation claims that the company failed to disclose its revenue outlook for the Commercial Services segment between February 24, 2026, and May 26, 2026, with investors needing to apply by August 4, 2026, to seek legal recourse as lead plaintiffs.
- BitGo Lawsuit Insights: The class action lawsuit against BitGo Holdings, Inc. alleges that the company did not adequately disclose the risks posed by falling digital asset prices to its financial performance, with a deadline of August 7, 2026, for investors to apply as lead plaintiffs to safeguard their interests.
- Law Firm Credentials: Holzer & Holzer, LLC is a top-rated securities litigation law firm that has recovered hundreds of millions for defrauded shareholders since its inception in 2000, emphasizing its commitment to providing robust legal representation for investors.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock dropped 50.55% from $101.53 to $50.21 following the February 19, 2026 announcement that its NHS-Galleri trial failed to meet its primary endpoint, severely impacting investor confidence and market performance.
- Class Action Initiated: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, with investors required to apply to lead the case by August 4, 2026.
- Trial Design Controversy: GRAIL claimed its NHS-Galleri trial was designed for three years to reduce late-stage cancer cases, but the lawsuit argues this timeframe was insufficient to demonstrate the primary endpoint, potentially misleading investors about the company's prospects.
- Legal Consequences and Impact: The lawsuit could result in significant financial liabilities for GRAIL, affecting its future fundraising capabilities and market reputation, thereby intensifying investor skepticism regarding its business model.
See More
